Search
Moderna Inc
MRNAAdd to Watchlist
66.930USD
+7.180+12.02%
Market hours （ET）Quotes delayed by 15 min
26.57BMarket Cap
LossP/E TTM
More Details of Moderna Inc Company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Moderna Inc Info
Ticker SymbolMRNA
Company nameModerna Inc
IPO dateDec 07, 2018
CEOBancel (Stephane)
Number of employees5800
Security typeOrdinary Share
Fiscal year-endDec 07
Address325 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16177146500
Websitehttps://www.modernatx.com/
Ticker SymbolMRNA
IPO dateDec 07, 2018
CEOBancel (Stephane)
Company Executives of Moderna Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.64M
+0.29%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
73.56K
+9.80%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
65.69K
+11.22%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
19.32K
+84.03%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
4.76K
+85.23%
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Francois Nader, M.D.
Dr. Francois Nader, M.D.
Independent Director
Independent Director
--
--
Ms. Tracey Franklin
Ms. Tracey Franklin
Chief People and Digital Technology Officer
Chief People and Digital Technology Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.64M
+0.29%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
73.56K
+9.80%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
65.69K
+11.22%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
19.32K
+84.03%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
4.76K
+85.23%
FAQs
Who are the top five shareholders of Moderna Inc?
The top five shareholders of Moderna Inc are: Dr. Stephen Hoge, M.D.
How many institutions hold shares of Moderna Inc (MRNA)?
As of 2026Q1, 1886 institutions hold shares of Moderna Inc, with a combined market value of approximately 313.06M, accounting for 78.90% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 10100814.00.
What is the biggest source of revenue for Moderna Inc?
In 2026Q1, the COVID business generated the highest revenue for Moderna Inc, amounting to 1.81B and accounting for 99.56% of total revenue.
